Filing Details

Accession Number:
0001181431-13-018836
Form Type:
4
Zero Holdings:
No
Publication Time:
2013-03-26 16:33:14
Reporting Period:
2013-03-20
Filing Date:
2013-03-26
Accepted Time:
2013-03-26 16:33:14
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1356576 Supernus Pharmaceuticals Inc SUPN Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1216917 Michael Bigham C/O Abingworth Management Inc
890 Winter Street, Suite 150
Waltham MA 02451
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2013-03-20 5,000 $5.17 5,000 No 4 P Indirect By Beatrice Emerson Bigham Trust U/A DTD 2/28/2001
Common Stock Acquisiton 2013-03-20 5,000 $5.20 5,000 No 4 P Indirect By Cabot Forbes Bigham Trust U/A DTD 10/11/1996
Common Stock Acquisiton 2013-03-20 10,000 $5.26 10,000 No 4 P Indirect By Michael F Bigham CRUT U/A DTD 11/23/1994
Common Stock Acquisiton 2013-03-22 15,000 $5.65 25,000 No 4 P Indirect By Michael F Bigham CRUT U/A DTD 11/23/1994
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect By Beatrice Emerson Bigham Trust U/A DTD 2/28/2001
No 4 P Indirect By Cabot Forbes Bigham Trust U/A DTD 10/11/1996
No 4 P Indirect By Michael F Bigham CRUT U/A DTD 11/23/1994
No 4 P Indirect By Michael F Bigham CRUT U/A DTD 11/23/1994
Reported Derivative Holdings
Sec. Name Sec. Type Price Date Expiration Date Amount Remaning Holdings Nature of Ownership
Common Stock Director Stock Option (Right to Buy) $7.90 2014-02-05 2023-02-05 8,722 8,722 Direct
Expiration Date Amount Remaning Holdings Nature of Ownership
2023-02-05 8,722 8,722 Direct
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.11 to $5.20, inclusive. The Reporting Person undertakes to provide to any security holder of Supernus Pharmaceuticals Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) through (4).
  2. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $5.17 to 5.20, inclusive.
  3. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $5.18 to 5.49, inclusive.
  4. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $5.53 to 5.68, inclusive.